3 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Untitled document
    3
    1. karim2001khoury 19 Feb 2026
      Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

      [Paper-level Aggregated] PMCID: PMC8887939

      Evidence Type(s): Prognostic, Oncogenic

      Justification: Prognostic: The text provides data on overall response rates (ORR), median duration of response (DoR), and median progression-free survival (PFS) associated with specific mutations, indicating their potential to predict clinical outcomes. Oncogenic: The mention of specific mutations (A775dupYVMA and G776delinsVC) in the context of their frequency and associated clinical outcomes suggests a role in tumorigenesis.

      Gene→Variant (gene-first): ERBB2(2064):A775dupYVMA ERBB2(2064):G776delinsVC

      Genes: ERBB2(2064)

      Variants: A775dupYVMA G776delinsVC

      CIViC paper-level aggregated PMC8887939
    2. karim2001khoury 19 Feb 2026
      The distribution pattern of the HER2 insertion mutations observed in our cohort was consistent with prior literature. The HER2 Y772_A775dupYVMA mutation was the most frequent and occurred in 65 (72.2%) patients, of whom

      [Paragraph-level] PMCID: PMC8887939 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Predictive, Diagnostic

      Justification: Predictive: The passage discusses the overall response rate (ORR) and median progression-free survival (PFS) associated with the HER2 insertion mutations, indicating a correlation with treatment response. Diagnostic: The mention of the frequency of the HER2 Y772_A775dupYVMA mutation in patients suggests its role in defining or classifying a specific disease subtype.

      Gene→Variant (gene-first): 2064:A775dupYVMA 2064:G776delinsVC

      Genes: 2064

      Variants: A775dupYVMA G776delinsVC

      CIViC paragraph-level PMC8887939 Predictive Diagnostic
    3. karim2001khoury 19 Feb 2026
      The distribution pattern of the HER2 insertion mutations observed in our cohort was consistent with prior literature. The HER2 Y772_A775dupYVMA mutation was the most frequent and occurred in 65 (72.2%) patients, of whom

      [Paragraph-level] PMCID: PMC8887939 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Predictive, Diagnostic

      Justification: Predictive: The passage discusses the overall response rate (ORR) and median progression-free survival (PFS) associated with the HER2 insertion mutations, indicating a correlation with treatment response. Diagnostic: The mention of the frequency of the HER2 Y772_A775dupYVMA mutation in patients suggests its role in defining or classifying a specific disease subtype.

      Gene→Variant (gene-first): 2064:A775dupYVMA 2064:G776delinsVC

      Genes: 2064

      Variants: A775dupYVMA G776delinsVC

      CIViC paragraph-level PMC8887939 Predictive Diagnostic
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC8887939/pdf/jco-40-710.pdf